ATP catabolism in tumors is primarily mediated by CD39 and CD73 (39–41), and high expression of these ecto-nucleotidases is strongly associated with poor clinical outcome for patients suffering a variety of cancer-types (3, 42, 43). Here, ENTPD1 is linked to cancer.